NCT02802423View on ClinicalTrials.gov

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

April 30, 2027

Study Completion Date

August 28, 2027

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

BLEX 404 Oral Liquid

BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.

All Listed Sponsors
lead

BioLite, Inc.

INDUSTRY